|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: FAU |
Gene summary for FAU |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | FAU | Gene ID | 2197 |
| Gene name | FAU ubiquitin like and ribosomal protein S30 fusion | |
| Gene Alias | FAU1 | |
| Cytomap | 11q13.1 | |
| Gene Type | protein-coding | GO ID | GO:0008150 | UniProtAcc | P35544 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 2197 | FAU | GSM4909281 | Human | Breast | IDC | 9.11e-29 | -2.96e-01 | 0.21 |
| 2197 | FAU | GSM4909282 | Human | Breast | IDC | 4.35e-17 | -2.10e-01 | -0.0288 |
| 2197 | FAU | GSM4909293 | Human | Breast | IDC | 5.05e-11 | -1.31e-01 | 0.1581 |
| 2197 | FAU | GSM4909294 | Human | Breast | IDC | 1.22e-02 | -2.08e-01 | 0.2022 |
| 2197 | FAU | GSM4909297 | Human | Breast | IDC | 1.41e-07 | -2.34e-01 | 0.1517 |
| 2197 | FAU | GSM4909298 | Human | Breast | IDC | 3.23e-11 | -1.51e-01 | 0.1551 |
| 2197 | FAU | GSM4909304 | Human | Breast | IDC | 3.53e-23 | 2.07e-01 | 0.1636 |
| 2197 | FAU | GSM4909306 | Human | Breast | IDC | 9.12e-07 | -1.39e-01 | 0.1564 |
| 2197 | FAU | GSM4909309 | Human | Breast | IDC | 3.61e-02 | 2.86e-02 | 0.0483 |
| 2197 | FAU | GSM4909311 | Human | Breast | IDC | 2.99e-14 | -7.56e-02 | 0.1534 |
| 2197 | FAU | GSM4909319 | Human | Breast | IDC | 2.17e-32 | -5.21e-01 | 0.1563 |
| 2197 | FAU | GSM4909320 | Human | Breast | IDC | 2.95e-08 | 1.73e-01 | 0.1575 |
| 2197 | FAU | GSM4909321 | Human | Breast | IDC | 2.53e-05 | 6.12e-02 | 0.1559 |
| 2197 | FAU | ctrl6 | Human | Breast | Precancer | 5.10e-03 | -2.17e-01 | -0.0061 |
| 2197 | FAU | brca2 | Human | Breast | Precancer | 1.68e-12 | -1.48e-01 | -0.024 |
| 2197 | FAU | brca3 | Human | Breast | Precancer | 4.59e-05 | -8.93e-02 | -0.0263 |
| 2197 | FAU | M5 | Human | Breast | IDC | 7.61e-03 | -4.24e-01 | 0.1598 |
| 2197 | FAU | NCCBC14 | Human | Breast | DCIS | 9.20e-13 | -3.94e-01 | 0.2021 |
| 2197 | FAU | NCCBC5 | Human | Breast | DCIS | 2.44e-08 | -2.80e-01 | 0.2046 |
| 2197 | FAU | P1 | Human | Breast | IDC | 1.71e-36 | -7.30e-01 | 0.1527 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Breast |  | IDC: Invasive ductal carcinoma |
| DCIS: Ductal carcinoma in situ | ||
| Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers | ||
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| GC |  | CAG: Chronic atrophic gastritis |
| CAG with IM: Chronic atrophic gastritis with intestinal metaplasia | ||
| CSG: Chronic superficial gastritis | ||
| GC: Gastric cancer | ||
| SIM: Severe intestinal metaplasia | ||
| WIM: Wild intestinal metaplasia | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0301018 | Breast | Precancer | Ribosome | 80/684 | 167/8465 | 7.33e-44 | 2.32e-41 | 1.77e-41 | 80 |
| hsa0517118 | Breast | Precancer | Coronavirus disease - COVID-19 | 81/684 | 232/8465 | 3.74e-32 | 2.36e-30 | 1.81e-30 | 81 |
| hsa0301019 | Breast | Precancer | Ribosome | 80/684 | 167/8465 | 7.33e-44 | 2.32e-41 | 1.77e-41 | 80 |
| hsa0517119 | Breast | Precancer | Coronavirus disease - COVID-19 | 81/684 | 232/8465 | 3.74e-32 | 2.36e-30 | 1.81e-30 | 81 |
| hsa0517124 | Breast | IDC | Coronavirus disease - COVID-19 | 86/867 | 232/8465 | 1.50e-28 | 9.72e-27 | 7.27e-27 | 86 |
| hsa0517134 | Breast | IDC | Coronavirus disease - COVID-19 | 86/867 | 232/8465 | 1.50e-28 | 9.72e-27 | 7.27e-27 | 86 |
| hsa0301044 | Breast | DCIS | Ribosome | 82/846 | 167/8465 | 8.69e-39 | 1.40e-36 | 1.03e-36 | 82 |
| hsa0517144 | Breast | DCIS | Coronavirus disease - COVID-19 | 86/846 | 232/8465 | 2.42e-29 | 1.56e-27 | 1.15e-27 | 86 |
| hsa0301054 | Breast | DCIS | Ribosome | 82/846 | 167/8465 | 8.69e-39 | 1.40e-36 | 1.03e-36 | 82 |
| hsa0517154 | Breast | DCIS | Coronavirus disease - COVID-19 | 86/846 | 232/8465 | 2.42e-29 | 1.56e-27 | 1.15e-27 | 86 |
| hsa0517120 | Cervix | CC | Coronavirus disease - COVID-19 | 111/1267 | 232/8465 | 1.82e-33 | 5.90e-31 | 3.49e-31 | 111 |
| hsa05171110 | Cervix | CC | Coronavirus disease - COVID-19 | 111/1267 | 232/8465 | 1.82e-33 | 5.90e-31 | 3.49e-31 | 111 |
| hsa0301025 | Cervix | HSIL_HPV | Ribosome | 80/459 | 167/8465 | 9.61e-58 | 2.82e-55 | 2.28e-55 | 80 |
| hsa0517125 | Cervix | HSIL_HPV | Coronavirus disease - COVID-19 | 91/459 | 232/8465 | 2.14e-56 | 3.13e-54 | 2.53e-54 | 91 |
| hsa0301035 | Cervix | HSIL_HPV | Ribosome | 80/459 | 167/8465 | 9.61e-58 | 2.82e-55 | 2.28e-55 | 80 |
| hsa0517135 | Cervix | HSIL_HPV | Coronavirus disease - COVID-19 | 91/459 | 232/8465 | 2.14e-56 | 3.13e-54 | 2.53e-54 | 91 |
| hsa05171 | Colorectum | AD | Coronavirus disease - COVID-19 | 113/2092 | 232/8465 | 9.90e-16 | 2.55e-14 | 1.63e-14 | 113 |
| hsa051711 | Colorectum | AD | Coronavirus disease - COVID-19 | 113/2092 | 232/8465 | 9.90e-16 | 2.55e-14 | 1.63e-14 | 113 |
| hsa051712 | Colorectum | SER | Coronavirus disease - COVID-19 | 98/1580 | 232/8465 | 3.33e-17 | 8.50e-16 | 6.17e-16 | 98 |
| hsa051713 | Colorectum | SER | Coronavirus disease - COVID-19 | 98/1580 | 232/8465 | 3.33e-17 | 8.50e-16 | 6.17e-16 | 98 |
| Page: 1 2 3 4 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| FAU | SNV | Missense_Mutation | c.271N>T | p.Pro91Ser | p.P91S | P62861,P35544 | protein_coding | deleterious(0.02) | benign(0.134) | TCGA-BH-A0B0-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | CR | |
| FAU | insertion | Frame_Shift_Ins | novel | c.125_126insG | p.Leu43ProfsTer9 | p.L43Pfs*9 | P62861,P35544 | protein_coding | TCGA-A8-A08H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| FAU | insertion | Frame_Shift_Ins | novel | c.123_124insTTGGGAGCATGGCCTCGTTTGTACCTCTGTGA | p.Leu43GlyfsTer31 | p.L43Gfs*31 | P62861,P35544 | protein_coding | TCGA-A8-A08H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| FAU | deletion | Frame_Shift_Del | novel | c.22delC | p.Gln8ArgfsTer8 | p.Q8Rfs*8 | P62861,P35544 | protein_coding | TCGA-EW-A2FV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | SD | ||
| FAU | SNV | Missense_Mutation | rs767227130 | c.322N>T | p.Arg108Trp | p.R108W | P62861,P35544 | protein_coding | tolerated(0.11) | benign(0.048) | TCGA-AA-3968-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| FAU | SNV | Missense_Mutation | c.391N>A | p.Ala131Thr | p.A131T | P62861,P35544 | protein_coding | deleterious(0.04) | probably_damaging(0.949) | TCGA-AD-6964-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Chemotherapy | folfox | PD | |
| FAU | SNV | Missense_Mutation | rs372080439 | c.325C>T | p.Arg109Trp | p.R109W | P62861,P35544 | protein_coding | tolerated(0.13) | benign(0.003) | TCGA-AF-3400-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Chemotherapy | 5-fu | SD |
| FAU | SNV | Missense_Mutation | c.335N>G | p.Tyr112Cys | p.Y112C | P62861,P35544 | protein_coding | deleterious(0) | possibly_damaging(0.86) | TCGA-AG-3892-01 | Colorectum | rectum adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| FAU | SNV | Missense_Mutation | novel | c.232N>T | p.Gly78Cys | p.G78C | P62861,P35544 | protein_coding | deleterious(0) | probably_damaging(0.98) | TCGA-AX-A1CE-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | SD |
| FAU | SNV | Missense_Mutation | novel | c.232N>T | p.Gly78Cys | p.G78C | P62861,P35544 | protein_coding | deleterious(0) | probably_damaging(0.98) | TCGA-AX-A2HD-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |